Why Vaxxinity Shares Are Trading Lower By Around 55%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Shares of Vaxxinity, Inc. (NASDAQ:VAXX) fell sharply during Monday's session after the company announced its intention to voluntarily delist and deregister its Class A common stock.
BenzingaApr 22 13:26 ET
MRIN, WISA and SMFL Among Mid-day Movers
Seeking AlphaApr 22 12:52 ET
12 Health Care Stocks Moving In Monday's Intraday Session
GainersNKGen Biotech (NASDAQ:NKGN) shares rose 33.8% to $1.48 during Monday's regular session. The company's market cap stands at $33.7 million. The company's, Q4 earnings came out 4 days ago. MSP Rec
BenzingaApr 22 12:31 ET
Inhibikase Therapeutics Files to Sell Common Stock, Warrants
Seeking AlphaApr 19 17:26 ET
Inhibikase Therapeutics Updates Shareholders on Future Plans
TipRanksApr 19 06:13 ET
Express News | Inhibikase Therapeutics - Upon Completion of Double-Blinded Phase of 201 Trial, We Expect to Request an End of Phase 2 Meeting With FDA by End of 2024
Moomoo 24/7Apr 18 16:30 ET
Express News | Inhibikase Therapeutics Issues Letter to Shareholders and Provides Update on Development Programs
Moomoo 24/7Apr 18 16:30 ET
Inhibikase Therapeutics Announces Apr. 5 Pre-IND Meeting With FDA For IkT-001Pro In Pulmonary Arterial Hypertension
Inhibikase Therapeutics Announces Apr. 5 Pre-IND Meeting With FDA For IkT-001Pro In Pulmonary Arterial Hypertension
BenzingaApr 3 08:07 ET
Buy Rating Affirmed for Inhibikase Therapeutics Amid Clinical Advancements and Regulatory Progress
TipRanksApr 2 15:15 ET
Inhibikase Therapeutics Full Year 2023 Earnings: EPS Misses Expectations
Yahoo FinanceApr 2 11:51 ET
Inhibikase Therapeutics Q4 EPS $(0.64) Beats $(0.85) Estimate, Sales $1.00K Down From $63.57K YoY
Inhibikase Therapeutics (NASDAQ:IKT) reported quarterly losses of $(0.64) per share which beat the analyst consensus estimate of $(0.85) by 24.71 percent. This is a 37.25 percent increase over losses
BenzingaMar 27 23:45 ET
Inhibikase Therapeutics GAAP EPS of -$3.57 Misses by $0.82, Revenue of $0.26M In-line
Seeking AlphaMar 27 16:44 ET
Express News | Inhibikase Therapeutics FY23 EPS $(3.57); Cash Position $13.3M As Of Dec. 31
Moomoo 24/7Mar 27 16:38 ET
Earnings Flash (IKT) INHIBIKASE THERAPEUTICS Posts 2023 Revenue $260,501
04:19 PM EDT, 03/27/2024 (MT Newswires) -- Earnings Flash (IKT) INHIBIKASE THERAPEUTICS Posts 2023 Revenue $260,501
MT NewswiresMar 27 16:19 ET
Press Release: Inhibikase Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Activity
Inhibikase Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Activity Company to host conference call on Thursday, March 28, 2024 at 8:00 a.m. ET BOSTON
Dow JonesMar 27 16:15 ET
Express News | HC Wainwright & Co. Reiterates Buy on Inhibikase Therapeutics, Maintains $27 Price Target
Moomoo 24/7Mar 7 11:26 ET
Inhibikase Therapeutics to Provide Trial Update for Risvodetinib at the 2024 International Conference on Alzheimer's and Parkinson's Diseases and Related Neurological Disorders
Globe NewswireMar 7 08:30 ET
Inhibikase Therapeutics Is Maintained at Buy by HC Wainwright & Co.
Inhibikase Therapeutics Is Maintained at Buy by HC Wainwright & Co.
Dow JonesMar 5 11:01 ET
Express News | HC Wainwright & Co. Maintains Buy on Inhibikase Therapeutics, Maintains $27 Price Target
Moomoo 24/7Mar 5 10:50 ET
Inhibikase Therapeutics Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 03/05/2024 1121.72% HC Wainwright & Co. $27 → $27 Maintains Buy 08/15/2023 1121.72% HC Wainwright & Co. →
BenzingaMar 5 10:49 ET
No Data
No Data